Business Context and Reporting Period
Company: ARTELO BIOSCIENCES, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2022
Event: Material Modification to Rights of Security Holders via a 1-for-15 Reverse Stock Split.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and capital structure adjustments.
Material Changes Versus Prior Period
- Reverse Stock Split: A 1-for-15 reverse split of issued and outstanding common stock is effective as of 12:01 a.m. Eastern Time on August 10, 2022.
- Share Count Reduction: Outstanding shares reduced from 42,594,000 to approximately 2,839,600.
- Authorized Shares:
- Common Stock: Reduced from 750,000,000 to 50,000,000.
- Preferred Stock: Reduced from 6,250,000 to 416,667.
- Warrant Adjustments:
- Public Warrants (ARTLW): Exercise price adjusted from $6.4575 to $96.8625 per post-split share.
- October 2020 Financing Warrants: Exercise price adjusted from $0.75 to $11.25 per post-split share.
- Fractional Shares: No fractional shares issued; holders entitled to fractional shares receive one whole share.
Guidance, Outlook, and Management Commentary
Purpose of Action: The reverse split is intended to improve the marketability and liquidity of the Common Stock and to regain compliance with the continued listing requirements of The Nasdaq Stock Market.
Management Commentary: The Board of Directors exercised authority under Nevada Revised Statutes 78.207 to effect the split without stockholder approval, as both authorized and outstanding shares are proportionally reduced.
Risks and Contingencies: The filing does not explicitly detail new risks, though the necessity of the split implies prior non-compliance with Nasdaq listing standards.
Important Facts for Investor Verification
- Verify the effective time of the split (August 10, 2022, 12:01 a.m. ET) to ensure proper trade settlement.
- Confirm the adjusted exercise prices for any held warrants ($96.8625 for public warrants; $11.25 for 2020 financing warrants).
- Check the updated share count (approx. 2.84 million outstanding) for dilution calculations.
- Monitor Nasdaq compliance status post-split to ensure the company maintains its listing.